Syndax Pharmaceuticals Inc financial data

Symbol
SNDX on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 484% % -35%
Quick Ratio 18% %
Debt-to-equity 320% % 757%
Return On Equity -207% % -156%
Return On Assets -49% % 16%
Operating Margin -158% % 89%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 88,200,596 shares 2.5%
Common Stock, Shares, Outstanding 87,405,979 shares 2%
Entity Public Float $799,200,000 USD -53%
Common Stock, Value, Issued $9,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 86,625,610 shares 1.2%
Weighted Average Number of Shares Outstanding, Diluted 86,625,610 shares 1.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $172,352,000 USD 628%
Research and Development Expense $258,784,000 USD 7.1%
General and Administrative Expense $44,917,000 USD 44%
Operating Income (Loss) $273,084,000 USD 20%
Nonoperating Income (Expense) $12,338,000 USD -159%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $285,422,000 USD 10%
Earnings Per Share, Basic -3.29 USD/shares 12%
Earnings Per Share, Diluted -3.29 USD/shares 12%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $134,930,000 USD -12%
Accounts Receivable, after Allowance for Credit Loss, Current $37,996,000 USD 400%
Inventory, Net $32,754,000 USD 8849%
Other Assets, Current $3,507,000 USD
Assets, Current $528,081,000 USD -12%
Property, Plant and Equipment, Net $181,000 USD
Operating Lease, Right-of-Use Asset $1,342,000 USD -34%
Other Assets, Noncurrent $0 USD -100%
Assets $529,706,000 USD -27%
Accounts Payable, Current $16,580,000 USD 43%
Employee-related Liabilities, Current $24,352,000 USD 68%
Liabilities, Current $120,116,000 USD 16%
Operating Lease, Liability, Noncurrent $1,578,000 USD 173%
Liabilities $465,076,000 USD 6.5%
Retained Earnings (Accumulated Deficit) $1,506,580,000 USD -23%
Stockholders' Equity Attributable to Parent $64,630,000 USD -78%
Liabilities and Equity $529,706,000 USD -27%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $95,162,000 USD -14%
Net Cash Provided by (Used in) Financing Activities $930,000 USD -57%
Net Cash Provided by (Used in) Investing Activities $94,142,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 86,905,343 shares 1.6%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $90,000 USD 100%
Deferred Tax Assets, Valuation Allowance $339,706,000 USD 31%
Deferred Tax Assets, Gross $339,706,000 USD 31%
Operating Lease, Liability $1,521,000 USD -26%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $318,813,000 USD -53%
Lessee, Operating Lease, Liability, to be Paid $1,735,000 USD -29%
Property, Plant and Equipment, Gross $606,000 USD 45%
Operating Lease, Liability, Current $470,000 USD -0.21%
Lessee, Operating Lease, Liability, to be Paid, Year Two $676,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $656,000 USD -0.15%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $214,000 USD -46%
Lessee, Operating Lease, Liability, to be Paid, Year Three $403,000 USD -40%
Deferred Tax Assets, Operating Loss Carryforwards $135,517,000 USD 213%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $143,000 USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $47,503,000 USD 10%
Interest Expense $233,000 USD -88%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%